CleneCLNN
CLNN
About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Employees: 85
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
89% more call options, than puts
Call options by funds: $327K | Put options by funds: $173K
30% more funds holding
Funds holding: 20 [Q3] → 26 (+6) [Q4]
9.57% less ownership
Funds ownership: 15.69% [Q3] → 6.13% (-9.57%) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
44% less capital invested
Capital invested by funds: $4.66M [Q3] → $2.59M (-$2.07M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
424%
upside
Avg. target
$27
515%
upside
High target
$31
606%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 27% 1-year accuracy 73 / 274 met price target | 424%upside $23 | Buy Maintained | 12 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 19% 1-year accuracy 77 / 411 met price target | 606%upside $31 | Buy Reiterated | 25 Feb 2025 |
Financial journalist opinion
Based on 4 articles about CLNN published over the past 30 days
Neutral
GlobeNewsWire
2 hours ago
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
Neutral
GlobeNewsWire
6 days ago
Clene to Present at the 37TH Annual Roth Conference
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings.
Neutral
Accesswire
1 week ago
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th. About Clene Inc. Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
Neutral
GlobeNewsWire
2 weeks ago
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA's request for supportive evidence of CNM-Au8's effect on NfL reduction observed in the HEALEY ALS Platform Trial Clene plans to submit a New Drug Application (NDA) in second-half 2025 SALT LAKE CITY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it has entered into an agreement with German-based APST Research GmbH (APST) to utilize its extensive NfL database to support the FDA-recommended analyses of CNM-Au8 ® 's effect on NfL decline in participants in ongoing Expanded Access Protocols (EAPs). APST maintains one of the largest comprehensive ALS repositories of people living with ALS, including demographic data, clinical data, ALS motor phenotypes and biomarker data, specifically, serum neurofilament light chain (sNfL).
Neutral
GlobeNewsWire
3 months ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it recently received written guidance from the Division of Neurology 1 (DN1), of the U.S. Food and Drug Administration (FDA) regarding a potential accelerated approval pathway for CNM-Au8 ® in ALS.
Negative
Zacks Investment Research
3 months ago
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago.
Neutral
GlobeNewsWire
5 months ago
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities purchase agreement with a healthcare focused institutional investor (“Healthcare Investor”) for the issuance and sale of 742,626 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, Clene also agreed to issue to the Healthcare Investor warrants to purchase up to 742,626 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one warrant to purchase one share of common stock at a combined purchase price of $4.713. The warrants have an exercise price of $4.82 per share, are immediately exercisable and will expire five years following the date of issuance.
Neutral
GlobeNewsWire
5 months ago
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the end of November 2024 to discuss CNM-Au8 development for ALS.
Neutral
GlobeNewsWire
6 months ago
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.
Positive
Zacks Investment Research
6 months ago
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
The consensus price target hints at an 873.5% upside potential for Clene (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Charts implemented using Lightweight Charts™